PCLAF and neoplasm: By week 4, the tumor volume was significantly reduced in the UbcH10 and KIAA0101 shRNA groups (p<0.05 compared to the model group), and the co-silenced group showed a superior effect on tumor growth inhibition (p<0.01 compared to the model group) (Fig. 6a).